So what’s wrong with Biotech financing today? What will it take to bring the Biotech market out of the doldrums and back into action? If you are having trouble finding financing for your next greatest idea then the only comforting news is that you are not alone....
Blog Series: 1 of 4 When it comes to venture capital and growth equity investments, the bottom line is the top line. If a company can grow its revenue, then odds are it will generate a strong return for its investors. Market due diligence is a key component of...
Blog Series 2 of 4 The Standard Market Due Diligence Process The typical market due diligence effort generally includes three components. To help explain each component and how they fit into the overall market assessment, we’ll illustrate this section using an...
Hello, We have all had a new boss in our life. This is an announcement concerning a different sort of BOSS. We here at Semaphore are excited to let you know more about our Business Operations/Strategy Service and the addition of David Friend, M.D., MBA as part of our...
Is 2011 a Wasteland or Playground? It seems my industry colleagues have continued to be wrongly optimistic about their personal income against a backdrop of continued and decided lack of confidence in the economy and their national governments. That appears to be the...
Our partner and colleague Jon Klein of The Topline Strategy Group explores one very public example. Earlier last month, Watson, a computer built by IBM, faced off against Ken Jennings and Brad Rutter, the two greatest Jeopardy players of all time and trounced them. Or...
